Stage III Gastric Cancer
14
1
2
10
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
7.1%
1 terminated out of 14 trials
90.9%
+4.4% vs benchmark
0%
0 trials in Phase 3/4
40%
4 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (14)
Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Immunonutritional Supplement After Total Gastrectomy in Patients With Stage III Gastric Cancer
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer